Propanc Biopharma, Inc. PPCB
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Propanc Biopharma, Inc. (PPCB) is a healthcare company listed in the US with a market value of about $2M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -230%.
About Propanc Biopharma
Propanc Biopharma is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 96967024% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$19M | -$59M | -$2M | -$3M | -$3M | -$2M | -$5M | -$6M | -$7M | -$8M |
| Free cash flow | -$6M | — | — | — | — | — | — | -$2M | — | — |
| EPS (diluted) | $-17.62 | $-371.22 | $-35513.26 | $-2700805.38 | $-73867027.07 | $-1200357.95 | $-288761108.24 | $-16459665777.57 | $-268201026229.70 | $-1680488564419.51 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -148.9% | -311.9% | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Propanc Biopharma pay a dividend?
Not currently.
Is Propanc Biopharma a good stock to buy?
We do not give buy or sell advice. Propanc Biopharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.